Creative Diagnostics Launches Effective Host Cell Protein ELISA Kits for Bioprocess Analysis

June 24, 2025 07:23 PM AEST | By EIN Presswire
 Creative Diagnostics Launches Effective Host Cell Protein ELISA Kits for Bioprocess Analysis
Image source: EIN Presswire

NEW YORK, NY, UNITED STATES, June 24, 2025 /EINPresswire.com/ -- Creative Diagnostics, a leading provider of assay kits, announces the Host Cell Protein ELISA Kits designed to support early biological agent development. These ELISA Kits provide HCP information to guide bioprocess optimization and reduce HCP levels which constitutes a significant component in bioprocess impurity analysis.

The residual HCP in the product may affect the safety and effectiveness of the product. A highly efficient, convenient and sensitive method is to use Enzyme-Linked Immunosorbent Assay (ELISA), which can comprehensively monitor and control residual HCP. Host Cell Protein ELISA Kits represent essential tools in biopharmaceutical development, providing critical analytical support for the detection and quantification of process-related impurities.

Creative Diagnostics' platform utilizes enzyme-linked immunosorbent assay (ELISA) technology to provide researchers with HCP assay kits for specific cell line expression systems. The Host Cell Protein (HCP) ELISA Kits offer an effective solution for biopharmaceutical quality control, and they have the advantage of high HCP coverage across diverse expression systems. Engineered for efficiency, these kits deliver rapid, user-friendly workflows with exceptional sensitivity, enabling precise detection of HCP contaminants. With specialized kits tailored for mammalian, bacterial, insect cell, and other gene expression systems, Creative Diagnostics' Host Cell Protein ELISA Kits provide researchers and manufacturers with a versatile toolkit, ensuring compliance with rigorous industry standards.

The HCP assay kits are tailored to specific cell line expression systems and support various applications across biopharmaceutical development. These kits help researchers detect residual HCP impurities in biologics at every stage of product development. These kits also enable precise detection and quantification of HCPs and offer validated data by their high sensitivity and accuracy. This promotes the safety and efficacy of drug products. Additionally, for quality control purposes, the HCP ELISA kits are ideal for process monitoring and are used to monitor the consistency of target molecules.

Creative Diagnostics provides customers with a robust range of HCP kits, including Mammalian HCP ELISA Kits, Bacterial HCP ELISA Kits, and other ELISA Kits. As a widely adopted platform in biopharmaceutical production, mammalian cells generate HCP and other process-related impurities during the production process. To quantify HCP from different mammalian recombinant systems, Creative Diagnostics offers Mammalian HCP ELISA Kits for different cell lines, including human lung adenocarcinoma cell line, human fetal lung fibroblasts, small hamster kidney fibroblasts, and Chinese hamster ovary cell line. In addition, Creative Diagnostics provides Bacterial HCP ELISA Kits which are designed to determine the presence of bacterial host cell protein contamination in products.

As an expert in the field of bioprocess impurity analysis, Creative Diagnostics has introduced Host Cell Protein ELISA Kits that help researchers easily tackle challenges in this area, providing effective research tools. For more information about the Host Cell Protein ELISA Kits and other ELISA Kits, please visit https://qbd.creative-diagnostics.com/products/host-cell-protein-elisa-kits.html.

About Creative Diagnostics

Creative Diagnostics is a leading provider of standardized testing kits and customized technical services for biopharmaceutical and biotech companies, CRO/CDMO, research institutions, and 3rd party testing institutions The company helps biopharmaceutical companies develop therapeutic proteins, vaccines, antibodies, plasma derivatives, and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release.

Thomas Schmitt
Creative Diagnostics
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.